Duchenne Muscular Dystrophy - Pipeline Review, H2 2011
Global Markets Direct’s, 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2011', provides an overview of the Duchenne Muscular Dystrophy therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy.
- A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular D
Duchenne Muscular Dystrophy – Pipeline Review, H2 2011 Duchenne Muscular Dystrophy - Pipeline Review, H2 2011 Reference Code: GMDHC1347IDB Publication Date: September 2011 Duchenne Muscular Dystrophy – Pipeline Review, H2 2011 GMDHC1347IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Duchenne Muscular Dystrophy – Pipeline Review, H2 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Duchenne Muscular Dystrophy Overview 8 Therapeutics Development 9 An Overview of Pipeline Products for Duchenne Muscular Dystrophy 9 Duchenne Muscular Dystrophy Therapeutics under Development by Companies 11 Duchenne Muscular Dystrophy Therapeutics under Investigation by Universities/Institutes 13 Late Stage Products 14 Comparative Analysis 14 Mid Clinical Stage Products 15 Comparative Analysis 15 Early Clinical Stage Products 16 Comparative Analysis 16 Discovery and Pre-Clinical Stage Products 17 Comparative Analysis 17 Duchenne Muscular Dystrophy Therapeutics - Products under Development by Companies 18 Duchenne Muscular Dystrophy Therapeutics - Products under Investigation by Universities/Institutes 20 Companies Involved in Duchenne Muscular Dystrophy Therapeutics Development 21 GlaxoSmithKline plc 21 AVI BioPharma Inc. 21 Galapagos NV 22 Summit Corporation plc 22 Santhera Pharmaceuticals Holding AG 23 Amsterdam Molecular Therapeutics BV 23 The Avicena Group, Inc. 24 Acceleron Pharma, Inc. 24 PTC Therapeutics, Inc. 25 UMN Pharma Inc. 25 Genethon 26 Prosensa Therapeutics B.V. 26 Duchenne Muscular Dystrophy - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 Ataluren - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 SMT C1100 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ACE-031 - Drug Profile 35 Duchenne Muscular Dystrophy – Pipeline Review, H2 2011 GMDHC1347IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Duchenne Muscular Dystrophy – Pipeline Review, H2 2011 Product Description 35 Mechanism of Action 35 R&D Progress 35 AVI-4658 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 AVI-5038 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 GSK2402968 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 DMD-02 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 PRO044 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 G100192 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 AMT-080 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 UMN-03 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 GLPG0492 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Gentamicin - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Catena - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Sunphenon EGCg - Drug Profile 51 Duchenne Muscular Dystrophy – Pipeline Review, H2 2011 GMDHC1347IDB / Pub September 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3) Duchenne Muscular Dystrophy – Pipeline Review, H2 2011 Product Description 51 Mechanism of Action 51 R&D Progress 51 Increlex - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 PRO045 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 PRO053 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 PRO052 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 PRO055 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Flavocoxid - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Duchenne Muscular Dystrophy Program - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Duchenne Muscular Dystrophy Therapeutics – Drug Profile Updates 60 Duchenne Muscular Dystrophy Therapeutics - Discontinued Products 65 Duchenne Muscular Dystrophy - Featured News 66 Aug 24, 2011: Santhera Obtains US Patent For Use Of Catena In Treatment Of Muscular Dystrophies 66 Aug 15, 2011: AVI BioPharma Initiates Dosing In Phase II Study Of Eteplirsen In Duchenne Muscular Dystrophy Patients 66 Jul 25, 2011: The Lancet Publishes Clinical Trial Data That Demonstrate Statistically Significant And Dose-Dependent Expression Of Dystrophin In Duchenne Muscular Dystrophy Patients Treated With AVI BioPharma's Eteplirsen 67 Jun 09, 2011: AVI BioPharma Provides Update On Initiation Of Eteplirsen Phase II Clinical Trial
Pages to are hidden for
"Duchenne Muscular Dystrophy - Pipeline Review, H2 2011"Please download to view full document